

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-77. canceled.

78. (Previously presented) A method of treating an immune disease in a subject, comprising parenterally administering to a subject that has been diagnosed with an immune disease a therapeutically effective amount of a sterile injectable composition comprising an antibody or antibody fragment specific to a marker associated with a B cell in a pharmaceutically acceptable injection vehicle.

79. (Previously presented) A method according to claim 78, wherein the subject has been diagnosed with immune thrombocytopenic purpura.

80. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is a Fv, single chain antibody, Fab, Fab', or F(ab')₂ fragment.

81. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is an intact antibody.

82. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is conjugated to a therapeutic agent.

83. (Currently amended) A method according to claim [[78]] 82, wherein the therapeutic agent is a cytotoxic agent.

84. (Previously presented) A method according to claim 83, wherein the cytotoxic agent is a therapeutic radioisotope.

85. (Currently amended) A method according to claim [[83]] 82, wherein the therapeutic agent is a drug.

86. (Currently amended) A method according to claim [[83]] 82, wherein the therapeutic agent is a toxin.

87. (Previously presented) A method according to claim 83, wherein said antibody or antibody fragment is an LL2 antibody or antibody fragment.

88. (Previously presented) A method according to claim 87, wherein said antibody or antibody fragment is an intact LL2 antibody.

89. (Previously presented) A method according to claim 87, wherein said antibody or antibody fragment is conjugated to a cytotoxic agent.

90. (Previously presented) A method according to claim 88, wherein said antibody or antibody fragment is conjugated to a cytotoxic agent.

91. (Previously presented) A method according to claim 89, wherein said cytotoxic agent is a drug.

92. (Previously presented) A method according to claim 90, wherein said cytotoxic agent is a drug.

93. (New) A method of treating an immune disease in a subject, comprising parenterally administering to a subject that has been diagnosed with an immune disease a therapeutically effective amount of a sterile injectable composition comprising an antibody specific to a marker associated with a B cell in a pharmaceutically acceptable injection vehicle.